IL209758A - Process for purifying or enriching coagulation factor viii - Google Patents

Process for purifying or enriching coagulation factor viii

Info

Publication number
IL209758A
IL209758A IL209758A IL20975810A IL209758A IL 209758 A IL209758 A IL 209758A IL 209758 A IL209758 A IL 209758A IL 20975810 A IL20975810 A IL 20975810A IL 209758 A IL209758 A IL 209758A
Authority
IL
Israel
Prior art keywords
purifying
factor viii
coagulation factor
enriching
enriching coagulation
Prior art date
Application number
IL209758A
Other languages
English (en)
Hebrew (he)
Other versions
IL209758A0 (en
Original Assignee
Octapharma Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40076764&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IL209758(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Octapharma Ag filed Critical Octapharma Ag
Publication of IL209758A0 publication Critical patent/IL209758A0/en
Publication of IL209758A publication Critical patent/IL209758A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A61K38/37—Factors VIII
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/57—Protease inhibitors from animals; from humans
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
    • B01D15/38—Selective adsorption, e.g. chromatography characterised by the separation mechanism involving specific interaction not covered by one or more of groups B01D15/265 and B01D15/30 - B01D15/36, e.g. affinity, ligand exchange or chiral chromatography
    • B01D15/3847—Multimodal interactions
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/36—Extraction; Separation; Purification by a combination of two or more processes of different types
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/647—Blood coagulation factors not provided for in a preceding group or according to more than one of the proceeding groups

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Analytical Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
IL209758A 2008-06-24 2010-12-05 Process for purifying or enriching coagulation factor viii IL209758A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US12940208P 2008-06-24 2008-06-24
EP08158893 2008-06-24
PCT/EP2009/057883 WO2009156430A1 (en) 2008-06-24 2009-06-24 A process of purifying coagulation factor viii

Publications (2)

Publication Number Publication Date
IL209758A0 IL209758A0 (en) 2011-02-28
IL209758A true IL209758A (en) 2014-02-27

Family

ID=40076764

Family Applications (3)

Application Number Title Priority Date Filing Date
IL209758A IL209758A (en) 2008-06-24 2010-12-05 Process for purifying or enriching coagulation factor viii
IL229583A IL229583B (en) 2008-06-24 2010-12-05 A preparation obtained by a process for the purification of coagulation factor viii
IL229583A IL229583A0 (en) 2008-06-24 2013-11-24 A process for the purification of coagulation factor viii

Family Applications After (2)

Application Number Title Priority Date Filing Date
IL229583A IL229583B (en) 2008-06-24 2010-12-05 A preparation obtained by a process for the purification of coagulation factor viii
IL229583A IL229583A0 (en) 2008-06-24 2013-11-24 A process for the purification of coagulation factor viii

Country Status (19)

Country Link
US (1) US8329871B2 (enExample)
EP (2) EP2537862B1 (enExample)
JP (1) JP5619738B2 (enExample)
KR (3) KR101804136B1 (enExample)
CN (1) CN102066417B (enExample)
AU (1) AU2009264282B2 (enExample)
BR (1) BRPI0914695B1 (enExample)
CA (1) CA2728047C (enExample)
DK (2) DK2537862T3 (enExample)
ES (2) ES2391613T3 (enExample)
IL (3) IL209758A (enExample)
MX (1) MX2010013908A (enExample)
PL (1) PL2300497T3 (enExample)
PT (1) PT2300497E (enExample)
RU (2) RU2698392C2 (enExample)
SI (1) SI2300497T1 (enExample)
UA (1) UA100901C2 (enExample)
WO (1) WO2009156430A1 (enExample)
ZA (1) ZA201009162B (enExample)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2167526B1 (en) 2007-07-11 2011-03-30 Novo Nordisk A/S Purification of factor viii using a mixed-mode or multimodal resin
EP2027875A1 (en) * 2007-08-23 2009-02-25 Octapharma AG A Process for Isolation and Purification of a Target Protein free of Prion Protein (PrPSC)
AU2009284113B2 (en) 2008-08-21 2015-05-14 Octapharma Ag Recombinantly produced human factor VIII and IX
KR101691443B1 (ko) * 2008-09-03 2016-12-30 옥타파마 아게 재조합에 의해 제조된 인자 ⅷ을 위한 신규한 보호 조성물
EP2326658A4 (en) * 2008-09-12 2013-04-10 Ge Healthcare Bio Sciences Ab REMOVAL OF REINFORCED PROTEIN AGGREGATES WITH MULTIMODAL ANION DERIVATIVES IN THE PRESENCE OF TWITTERS WITHOUT PROTEINS
CN102858797B (zh) * 2010-03-30 2016-05-11 奥克塔法马股份有限公司 纯化生长因子蛋白的方法
TR201911082T4 (tr) * 2010-03-30 2019-08-21 Octapharma Ag K vitaminine bağımlı proteinlerin saflaştırılması için bir işlem.
ES2639641T3 (es) 2010-04-20 2017-10-27 Octapharma Ag Nuevo agente estabilizante para proteínas farmacéuticas
WO2012049285A1 (en) 2010-10-14 2012-04-19 Octapharma Ag A method for the quantitative glycosylation analysis of proteins
JP5947802B2 (ja) * 2010-11-05 2016-07-06 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト ミックスモードクロマトグラフィーによる抗体捕捉の最適化方法
KR101980164B1 (ko) * 2011-05-13 2019-05-20 옥타파마 아게 재조합 ｆｖｉｉｉ의 생산에서 진핵 세포의 생산성을 증가시키는 방법
ES2613723T3 (es) 2011-06-17 2017-05-25 School Juridical Person Higashi-Nippon-Gakuen Método de medición del tiempo de coagulación sanguínea para detectar anticoagulantes de Lupus
EP2771358A4 (en) * 2011-10-26 2015-08-26 Bio Rad Laboratories ELIMINATION OF VIRAL AGENTS IN MIXED MODE CHROMATOGRAPHY
AU2013334644B2 (en) * 2012-10-24 2018-07-12 Genzyme Corporation Elution of biomolecules from multi-modal resins using mes and mops as mobile phase modifiers
US20140154233A1 (en) * 2012-12-05 2014-06-05 Csl Limited Method of purifying therapeutic proteins
US10188965B2 (en) 2012-12-05 2019-01-29 Csl Behring Gmbh Hydrophobic charge induction chromatographic depletion of a protein from a solution
CN103880947B (zh) * 2012-12-21 2016-01-13 武汉禾元生物科技股份有限公司 一种分离纯化高纯度重组人血清白蛋白的层析方法
HK1219964A1 (zh) 2013-03-08 2017-04-21 Genzyme Corporation 治疗性蛋白药物物质的整合连续制造
US20160130361A1 (en) * 2013-06-13 2016-05-12 Biogen Ma Inc. Anti-factor viii antibodies or uses thereof
CA2910770C (en) 2013-07-12 2018-02-27 Merck Patent Gmbh Removal of fragments from a sample containing a target protein using activated carbon
EP3043813B1 (en) * 2013-08-08 2021-01-13 Bioverativ Therapeutics Inc. Purification of chimeric fviii molecules
KR101988705B1 (ko) 2013-09-24 2019-06-12 화이자 인코포레이티드 재조합 인간 응고 인자 Xa 단백질의 이질적 집단을 포함하는 조성물
TWI709569B (zh) 2014-01-17 2020-11-11 美商健臻公司 無菌層析樹脂及其用於製造方法的用途
TWI671312B (zh) * 2014-01-17 2019-09-11 美商健臻公司 無菌層析法及製法
EP3097118B1 (en) * 2014-01-20 2018-07-18 Octapharma AG A process for manufacturing factor viii having an improved ratio of fviii:c/fviii:ag
CA2936829C (en) * 2014-01-24 2024-05-28 Am-Pharma B.V. Downstream processing of an alkaline phosphatase
KR102382402B1 (ko) 2014-02-04 2022-04-01 바이오젠 엠에이 인코포레이티드 번역 후 변형을 강화시키기 위한 통류 방식 양이온 교환 크로마토그래피의 용도
CN104861060A (zh) * 2014-02-21 2015-08-26 神州细胞工程有限公司 一种纯化凝血因子viii的方法
CN106232614A (zh) 2014-05-29 2016-12-14 新加坡科技研究局 蛋白质提取方法
US10626164B2 (en) * 2014-07-25 2020-04-21 Csl Limited Purification of VWF
GB201506117D0 (en) 2015-04-10 2015-05-27 Ge Healthcare Bio Sciences Ab Method for chromatography
GB201506113D0 (en) 2015-04-10 2015-05-27 Ge Healthcare Bio Sciences Ab Method for chromatography
WO2016207328A1 (en) * 2015-06-24 2016-12-29 Glycotope Gmbh PROCESS FOR THE PURIFICATION OF γ-CARBOXYLATED POLYPEPTIDES
EP3205665A1 (en) 2016-02-11 2017-08-16 Octapharma AG Method of separating factor viii from blood products
GB201617240D0 (en) * 2016-10-11 2016-11-23 Profactor Pharma Ltd Purification process
CN111183151B (zh) * 2017-06-23 2024-06-07 武田药品工业株式会社 因子viii亚种的纯化
CN107226859B (zh) * 2017-08-10 2020-11-24 博雅生物制药集团股份有限公司 一种人凝血因子ⅷ的制备方法
US11584777B2 (en) 2017-08-31 2023-02-21 Green Cross Corporation Method for purifying a sulfatase protein
CA3080656A1 (en) 2017-10-30 2019-05-09 Baxalta GmbH Environmentally compatible detergents for inactivation of lipid-enveloped viruses
AU2019332764B2 (en) 2018-08-31 2025-05-29 Genzyme Corporation Sterile chromatography resin and use thereof in manufacturing processes
EP4093745A4 (en) * 2020-01-20 2024-03-06 Wuxi Biologics Ireland Limited NEW WASH BUFFER SOLUTION FOR AFFINITY CHROMATOGRAPHY
CN118217951B (zh) * 2024-04-01 2025-05-23 山东建筑大学 一种水中的高纯度磷回收装置和方法

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4540573A (en) 1983-07-14 1985-09-10 New York Blood Center, Inc. Undenatured virus-free biologically active protein derivatives
US5605884A (en) * 1987-10-29 1997-02-25 Rhone-Poulenc Rorer Pharmaceuticals Inc. Factor VIII formulations in high ionic strength media
US5316680A (en) * 1992-10-21 1994-05-31 Cornell Research Foundation, Inc. Multimodal chromatographic separation media and process for using same
JPH08506710A (ja) 1993-06-11 1996-07-16 ノーザン・テレコム・リミテッド ユーザ制御呼管理サービス方法および装置
DE4337573C1 (de) * 1993-11-04 1995-05-18 Octapharma Ag Verfahren zur Herstellung einer virusinaktivierten Faktor VIII enthaltenden Fraktion mittels chromatographischer Methoden
SE9403915D0 (sv) 1994-11-14 1994-11-14 Annelie Almstedt Process A
AUPR638801A0 (en) * 2001-07-13 2001-08-09 Life Therapeutics Limited Factor viii separation
WO2005082483A1 (en) * 2004-02-27 2005-09-09 Ge Healthcare Bio-Sciences Ab A process for the purification of antibodies
PL1765866T3 (pl) * 2004-06-07 2014-06-30 Therapure Biopharma Inc Wydzielanie białek osocza lub surowicy
EP1707634A1 (en) * 2005-03-29 2006-10-04 Octapharma AG Method for isolation of recombinantly produced proteins
FR2887883B1 (fr) * 2005-06-29 2007-08-31 Lab Francais Du Fractionnement Procede de separation des proteines fibrinogene, facteur xiii et colle biologique d'une fraction plasmatique solubilisee et de preparation de concentres lyophilises desdites proteines
EP1739179A1 (en) 2005-06-30 2007-01-03 Octapharma AG Serum-free stable transfection and production of recombinant human proteins in human cell lines
WO2008008975A2 (en) * 2006-07-14 2008-01-17 Genentech, Inc. Refolding of recombinant proteins
RU2324495C1 (ru) * 2006-08-31 2008-05-20 Федеральное государственное унитарное предприятие "Научно-производственное объединение по медицинским иммунобиологическим препаратам "Микроген" Министерства здравоохранения Российской Федерации Способ получения препарата фактора свертывания viii крови человека
CA2674881A1 (en) * 2007-02-01 2008-08-07 Baxter International Inc. Fviii-independent fix-mutant proteins for hemophilia a treatment
JP2010529155A (ja) * 2007-06-13 2010-08-26 ツェー・エス・エル・ベーリング・ゲー・エム・ベー・ハー 出血性疾患の治療及び予防的処置における血管外投与のためのｖｗｆ安定化ｆｖｉｉｉ製剤及びｆｖｉｉｉなしのｖｗｆ製剤の使用
EP2167526B1 (en) * 2007-07-11 2011-03-30 Novo Nordisk A/S Purification of factor viii using a mixed-mode or multimodal resin
GB0723712D0 (en) * 2007-12-04 2008-01-16 Apitope Technology Bristol Ltd Peptides
DE102008032361A1 (de) * 2008-07-10 2010-01-21 Csl Behring Gmbh Der Einsatz von Faktor VIII und vWF bzw. vWF-enthaltenden Konzentraten zur Therapie der durch Thrombocyten-Inhibitoren induzierte Koagulopathie

Also Published As

Publication number Publication date
BRPI0914695A2 (pt) 2015-10-20
KR20110038634A (ko) 2011-04-14
JP5619738B2 (ja) 2014-11-05
MX2010013908A (es) 2011-01-21
US20110160435A1 (en) 2011-06-30
BRPI0914695B1 (pt) 2022-04-19
DK2537862T3 (en) 2015-06-15
UA100901C2 (ru) 2013-02-11
CA2728047C (en) 2019-07-30
SI2300497T1 (sl) 2013-02-28
RU2015141849A (ru) 2018-12-28
KR20160104740A (ko) 2016-09-05
RU2011102437A (ru) 2012-07-27
PT2300497E (pt) 2012-10-30
EP2537862B1 (en) 2015-03-18
ZA201009162B (en) 2011-10-26
ES2538706T3 (es) 2015-06-23
CN102066417B (zh) 2015-11-25
RU2015141849A3 (enExample) 2018-12-28
IL229583A0 (en) 2014-01-30
EP2300497B1 (en) 2012-08-08
IL209758A0 (en) 2011-02-28
PL2300497T3 (pl) 2013-02-28
CA2728047A1 (en) 2009-12-30
KR101700722B1 (ko) 2017-01-31
KR101804136B1 (ko) 2017-12-04
AU2009264282A1 (en) 2009-12-30
RU2698392C2 (ru) 2019-08-26
RU2567811C2 (ru) 2015-11-10
EP2537862A1 (en) 2012-12-26
KR20170102065A (ko) 2017-09-06
AU2009264282B2 (en) 2013-04-18
EP2300497A1 (en) 2011-03-30
CN102066417A (zh) 2011-05-18
WO2009156430A1 (en) 2009-12-30
ES2391613T3 (es) 2012-11-28
IL229583B (en) 2018-03-29
DK2300497T3 (da) 2012-10-29
US8329871B2 (en) 2012-12-11
JP2011525523A (ja) 2011-09-22

Similar Documents

Publication Publication Date Title
IL209758A (en) Process for purifying or enriching coagulation factor viii
AP3333A (en) Process for the manufacture of hydrocarbons of biological origin
EP2334328A4 (en) METHOD FOR CLEANING VIRUSES
ZA201101127B (en) Treatment of tailings streams
IL208354A0 (en) Methods of treatment
IL215082A0 (en) Methods of purifying small modular immunopharmaceutical proteins
EP2394958A4 (en) DDR TYPE ZEOLITE POWDER, AND PROCESS FOR PRODUCING DER TYPE ZEOLITE POWDER
EP2366794A4 (en) PROCESS FOR PRODUCTION OF POLY-3-HYDROXYALCANOATE AND AGGLOMERATE OF POLY-3-HYDROXYALCANOATE
EP2313103A4 (en) PROCESS FOR TREATING A BLÉPHARITE
EP2410855A4 (en) PROCESS FOR THE PREPARATION OF ALOGLIPTIN
EP2271615A4 (en) NEW PROCESS FOR THE PREPARATION OF THE IOPROMIDE
IL208732A0 (en) Methods for enhanced production of bone morphogenetic proteins
EP2350641A4 (en) Methods of Treatment
EP2400974A4 (en) SYNTHETIC DOUBLE BLOCK CO-POLYPEPTIDE HYDROGELS FOR USE IN THE CENTRAL NERVOUS SYSTEM
GB0808908D0 (en) Purification process
GB0816242D0 (en) Method of purifying protien complexes
EP2259269A4 (en) METHOD FOR MANUFACTURING RADIOACTIVE STRONTIUM
IL207911A0 (en) Method for the purification of biological macromolecules
IL211851A0 (en) Method for producing and purifying trifluoromethanesulfinic acid
GB0816618D0 (en) Process of Waste Treatment
GB0818228D0 (en) Purification process
GB2459738B (en) Method of purification
EP2303284A4 (en) METHOD FOR TREATING BIPOLAR DISORDER
IL218260A0 (en) Method for purifying gla-domain coagulation proteins
DE112009003270A5 (de) Filtereinsatz und verfahren zur herstellung des filtereinsatzes

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
KB Patent renewed
KB Patent renewed